P220029/S003: Optilume BPH Catheter System
FDA’s recorded scope: Approval of the revised protocol for the post-approval study (PAS)
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 2 FDA records to the applicant name Urotronic, Inc.. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Dec 12, 2025 to Dec 15, 2025. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QXB appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P220029, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 2495 Xenium Ln., Minneapolis, MN, 55449. Recorded on P220029/S003, decision dated Dec 15, 2025.
Drug coated prostatic dilation catheter for benign prostatic hyperplasia.
FDA’s recorded scope: Approval of the revised protocol for the post-approval study (PAS)
FDA’s recorded scope: a change of an additional pre-dilation catheter supplier manufacturing site
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Optilume BPH Catheter SystemP220029/S003 | Urotronic, Inc. | PMA supplement | Dec 15, 2025 | FDA |
Optilume BPH Catheter SystemP220029/S004 | Urotronic, Inc. | PMA supplement | Dec 12, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.